PubRank

Manuel Battegay

Author PubWeight™ 208.58‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010 7.86
2 Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study. Clin Infect Dis 2011 4.31
3 Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy. Clin Infect Dis 2005 3.57
4 CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. Arch Intern Med 2003 3.41
5 Association of alcohol consumption and HIV surrogate markers in participants of the swiss HIV cohort study. J Acquir Immune Defic Syndr 2013 3.02
6 Antiretroviral therapy reduces markers of endothelial and coagulation activation in patients infected with human immunodeficiency virus type 1. J Infect Dis 2002 2.46
7 Immune reconstitution in HIV-infected patients. Clin Infect Dis 2004 2.38
8 CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy. Clin Infect Dis 2008 2.35
9 Response to combination antiretroviral therapy: variation by age. AIDS 2008 2.28
10 Molecular epidemiology reveals long-term changes in HIV type 1 subtype B transmission in Switzerland. J Infect Dis 2010 2.21
11 Incidence and risk factors for chronic elevation of alanine aminotransferase levels in HIV-infected persons without hepatitis b or c virus co-infection. Clin Infect Dis 2010 2.17
12 Hodgkin lymphoma in the Swiss HIV Cohort Study. Blood 2009 2.15
13 Suicide in HIV-infected individuals and the general population in Switzerland, 1988-2008. Am J Psychiatry 2009 2.12
14 Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008. Arch Intern Med 2010 2.05
15 Thrombocytopenia is associated with an increased risk of cancer during treated HIV disease. AIDS 2014 2.02
16 Correlates of self-reported nonadherence to antiretroviral therapy in HIV-infected patients: the Swiss HIV Cohort Study. J Acquir Immune Defic Syndr 2006 1.95
17 Mortality in the Swiss HIV Cohort Study (SHCS) and the Swiss general population. Lancet 2003 1.94
18 Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders. J Infect Dis 2005 1.93
19 All cause mortality in the Swiss HIV Cohort Study from 1990 to 2001 in comparison with the Swiss population. AIDS 2004 1.91
20 Migrants from Sub-Saharan Africa in the Swiss HIV Cohort Study: access to antiretroviral therapy, disease progression and survival. AIDS 2003 1.87
21 Association of a pool of HIV-1 with erythrocytes in vivo: a cohort study. Lancet 2002 1.85
22 The HIV care cascade in Switzerland: reaching the UNAIDS/WHO targets for patients diagnosed with HIV. AIDS 2015 1.84
23 Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types. Arch Intern Med 2007 1.80
24 Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection. J Infect Dis 2005 1.80
25 Durability and outcome of initial antiretroviral treatments received during 2000--2005 by patients in the Swiss HIV Cohort Study. J Infect Dis 2008 1.76
26 Longitudinal analysis of patterns and predictors of changes in self-reported adherence to antiretroviral therapy: Swiss HIV Cohort Study. J Acquir Immune Defic Syndr 2010 1.75
27 Polyfunctional HCV-specific T-cell responses are associated with effective control of HCV replication. Eur J Immunol 2008 1.70
28 Role of retroviral restriction factors in the interferon-α-mediated suppression of HIV-1 in vivo. Proc Natl Acad Sci U S A 2012 1.65
29 Ambiguous nucleotide calls from population-based sequencing of HIV-1 are a marker for viral diversity and the age of infection. Clin Infect Dis 2011 1.64
30 High risk behaviour and fertility desires among heterosexual HIV-positive patients with a serodiscordant partner--two challenging issues. Swiss Med Wkly 2003 1.64
31 Phylogenetic approach reveals that virus genotype largely determines HIV set-point viral load. PLoS Pathog 2010 1.63
32 The role of CFTR and SPINK-1 mutations in pancreatic disorders in HIV-positive patients: a case-control study. AIDS 2004 1.63
33 Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy. AIDS 2002 1.63
34 Comparative transcriptomics of extreme phenotypes of human HIV-1 infection and SIV infection in sooty mangabey and rhesus macaque. J Clin Invest 2011 1.61
35 Non-Hodgkin lymphoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. AIDS 2008 1.60
36 Evidence of viral adaptation to HLA class I-restricted immune pressure in chronic hepatitis C virus infection. J Virol 2006 1.54
37 Incidence and outcome of progressive multifocal leukoencephalopathy over 20 years of the Swiss HIV Cohort Study. Clin Infect Dis 2009 1.53
38 Cellular immune responses to HCV core increase and HCV RNA levels decrease during successful antiretroviral therapy. Gut 2010 1.53
39 Long-term trends of HIV type 1 drug resistance prevalence among antiretroviral treatment-experienced patients in Switzerland. Clin Infect Dis 2009 1.50
40 Prior therapy influences the efficacy of lamivudine monotherapy in patients with lamivudine-resistant HIV-1 infection. J Acquir Immune Defic Syndr 2010 1.49
41 Effect of early antiretroviral therapy during primary HIV-1 infection on cell-associated HIV-1 DNA and plasma HIV-1 RNA. Antivir Ther 2011 1.44
42 Viral suppression rates in salvage treatment with raltegravir improved with the administration of genotypic partially active or inactive nucleoside/tide reverse transcriptase inhibitors. J Acquir Immune Defic Syndr 2011 1.44
43 A prospective trial of structured treatment interruptions in human immunodeficiency virus infection. Arch Intern Med 2003 1.44
44 Intranasal influenza vaccine in a working population. Clin Infect Dis 2004 1.43
45 Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir. AIDS 2012 1.42
46 Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study. Antivir Ther 2005 1.36
47 JC virus-specific immune responses in human immunodeficiency virus type 1 patients with progressive multifocal leukoencephalopathy. J Virol 2009 1.32
48 Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study. Antivir Ther 2010 1.30
49 Infrequent transmission of HIV-1 drug-resistant variants. Antivir Ther 2004 1.30
50 Estimating the net contribution of interleukin-28B variation to spontaneous hepatitis C virus clearance. Hepatology 2011 1.30
51 A smoking cessation programme in HIV-infected individuals: a pilot study. Antivir Ther 2006 1.27
52 Exclusive Staphylococcus aureus throat carriage: at-risk populations. Arch Intern Med 2009 1.24
53 Impact of a national HIV voluntary counselling and testing (VCT) campaign on VCT in a rural hospital in Tanzania. Trop Med Int Health 2010 1.24
54 Early antiretroviral therapy during primary HIV-1 infection results in a transient reduction of the viral setpoint upon treatment interruption. PLoS One 2011 1.24
55 Characteristics and treatment outcome of cerebrospinal fluid shunt-associated infections in adults: a retrospective analysis over an 11-year period. Clin Infect Dis 2008 1.23
56 Outcomes of early switching from intravenous to oral antibiotics on medical wards. J Antimicrob Chemother 2009 1.22
57 Viral hepatitis and rapid diagnostic test based screening for HBsAg in HIV-infected patients in rural Tanzania. PLoS One 2013 1.21
58 Extended spectrum ß-lactamase-producing Escherichia coli in neonatal care unit. Emerg Infect Dis 2010 1.21
59 HIV patients developing primary CNS lymphoma lack EBV-specific CD4+ T cell function irrespective of absolute CD4+ T cell counts. PLoS Med 2007 1.20
60 Systemic antibody responses to gut commensal bacteria during chronic HIV-1 infection. Gut 2011 1.18
61 Incidence of HIV-1 drug resistance among antiretroviral treatment-naive individuals starting modern therapy combinations. Clin Infect Dis 2011 1.17
62 TB in a low-incidence country: differences between new immigrants, foreign-born residents and native residents. Am J Med 2007 1.16
63 Self-reported non-adherence to antiretroviral therapy repeatedly assessed by two questions predicts treatment failure in virologically suppressed patients. Antivir Ther 2008 1.14
64 Humoral immunity to HIV-1: kinetics of antibody responses in chronic infection reflects capacity of immune system to improve viral set point. Blood 2004 1.14
65 Improved antiretroviral treatment outcome in a rural African setting is associated with cART initiation at higher CD4 cell counts and better general health condition. BMC Infect Dis 2011 1.14
66 Virosomal influenza-vaccine induced immunity in HIV-infected individuals with high versus low CD4+ T-cell counts: clues towards a rational vaccination strategy. AIDS 2010 1.11
67 Mycobacterium tuberculosis transmission in a country with low tuberculosis incidence: role of immigration and HIV infection. J Clin Microbiol 2011 1.10
68 Treatment-naive individuals are the major source of transmitted HIV-1 drug resistance in men who have sex with men in the Swiss HIV Cohort Study. Clin Infect Dis 2013 1.08
69 HIV-1 p24 may persist during long-term highly active antiretroviral therapy, increases little during short treatment breaks, and its rebound after treatment stop correlates with CD4(+) T cell loss. J Acquir Immune Defic Syndr 2005 1.07
70 High colonization rates of extended-spectrum β-lactamase (ESBL)-producing Escherichia coli in Swiss travellers to South Asia- a prospective observational multicentre cohort study looking at epidemiology, microbiology and risk factors. BMC Infect Dis 2014 1.06
71 Ageing with HIV: medication use and risk for potential drug-drug interactions. J Antimicrob Chemother 2011 1.04
72 HIV infection disrupts the sympatric host-pathogen relationship in human tuberculosis. PLoS Genet 2013 1.04
73 The role of migration and domestic transmission in the spread of HIV-1 non-B subtypes in Switzerland. J Infect Dis 2011 1.03
74 Self-reported alcohol consumption and its association with adherence and outcome of antiretroviral therapy in the Swiss HIV Cohort Study. Antivir Ther 2009 1.03
75 Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir. Clin Infect Dis 2008 1.02
76 Interruptions of cART limits CD4 T-cell recovery and increases the risk for opportunistic complications and death. AIDS 2011 1.02
77 Uptake of guidelines on prevention of mother-to-child transmission of HIV in rural Tanzania: time for change. Swiss Med Wkly 2013 1.02
78 Impact of previous virological treatment failures and adherence on the outcome of antiretroviral therapy in 2007. PLoS One 2009 1.01
79 Appropriateness of antibiotic treatment in intravenous drug users, a retrospective analysis. BMC Infect Dis 2008 1.00
80 CD4+ T-cell count increase in HIV-1-infected patients with suppressed viral load within 1 year after start of antiretroviral therapy. Antivir Ther 2007 0.99
81 Treatment initiation with zidovudine-containing potent antiretroviral therapy impairs CD4 cell count recovery but not clinical efficacy. AIDS 2007 0.99
82 Contribution of genome-wide significant single-nucleotide polymorphisms and antiretroviral therapy to dyslipidemia in HIV-infected individuals: a longitudinal study. Circ Cardiovasc Genet 2009 0.99
83 Eligibility for and outcome of hepatitis C treatment of HIV-coinfected individuals in clinical practice: the Swiss HIV cohort study. Antivir Ther 2006 0.99
84 A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection. J Infect Dis 2002 0.99
85 Choice of Initial Combination Antiretroviral Therapy in Individuals With HIV Infection: Determinants and Outcomes. Arch Intern Med 2012 0.98
86 Hepatitis B virus infection is associated with impaired immunological recovery during antiretroviral therapy in the Swiss HIV cohort study. J Infect Dis 2013 0.97
87 Origin of minority drug-resistant HIV-1 variants in primary HIV-1 infection. J Infect Dis 2013 0.96
88 Scabies outbreak in an intensive care unit with 1,659 exposed individuals--key factors for controlling the outbreak. Infect Control Hosp Epidemiol 2009 0.96
89 Self-reported nonadherence to antiretroviral therapy as a predictor of viral failure and mortality. AIDS 2015 0.95
90 Antiretroviral therapy after cryptococcal meningitis. N Engl J Med 2014 0.95
91 HLA-Bw4 homozygosity is associated with an impaired CD4 T cell recovery after initiation of antiretroviral therapy. Clin Infect Dis 2008 0.95
92 Persistent apoptosis in HIV-1-infected individuals receiving potent antiretroviral therapy is associated with poor recovery of CD4 T lymphocytes. J Acquir Immune Defic Syndr 2004 0.95
93 Symptom management in HIV/AIDS: advancing the conceptualization. ANS Adv Nurs Sci 2005 0.94
94 CD4(+) T cell count decreases by ethnicity among untreated patients with HIV infection in South Africa and Switzerland. J Infect Dis 2009 0.94
95 Acute renal failure on immune reconstitution in an HIV-positive patient with miliary tuberculosis. Clin Infect Dis 2004 0.93
96 Stable partnership and progression to AIDS or death in HIV infected patients receiving highly active antiretroviral therapy: Swiss HIV cohort study. BMJ 2004 0.93
97 HIV-1-infected patients with focal neurologic signs: diagnostic role of PCR for Toxoplasma gondii, Epstein-Barr virus, and JC virus. Clin Microbiol Infect 1998 0.92
98 Meta-analysis of randomized controlled trials of simplified versus continued protease inhibitor-based antiretroviral therapy in HIV-1-infected patients. AIDS 2003 0.92
99 Carriage of Staphylococcus aureus among injection drug users: lower prevalence in an injection heroin maintenance program than in an oral methadone program. Infect Control Hosp Epidemiol 2004 0.92
100 Productivity costs and determinants of productivity in HIV-infected patients. Clin Ther 2004 0.92
101 Virological and immunological responses to efavirenz or boosted lopinavir as first-line therapy for patients with HIV. Antivir Ther 2009 0.92
102 Is unsafe sexual behaviour increasing among HIV-infected individuals? AIDS 2004 0.91
103 Treatment and prognosis of AIDS-related lymphoma in the era of highly active antiretroviral therapy: findings from the Swiss HIV Cohort Study. Antivir Ther 2007 0.91
104 No risk of surgical site infections from residual bacteria after disinfection with povidone-iodine-alcohol in 1014 cases: a prospective observational study. Ann Surg 2012 0.91
105 Empirical use of antibiotics and adjustment of empirical antibiotic therapies in a university hospital: a prospective observational study. BMC Infect Dis 2007 0.89
106 Efavirenz in an obese HIV-infected patient--a report and an in vitro-in vivo extrapolation model indicate risk of underdosing. Antivir Ther 2012 0.88
107 Effects of cognitive behavioral stress management on HIV-1 RNA, CD4 cell counts and psychosocial parameters of HIV-infected persons. AIDS 2008 0.88
108 A rifampicin-containing antibiotic treatment improves outcome of staphylococcal deep sternal wound infections. J Antimicrob Chemother 2010 0.88
109 Gastrointestinal bleeding associated with rivaroxaban administration in a treated patient infected with human immunodeficiency virus. Swiss Med Wkly 2014 0.87
110 Pulmonary infections diagnosed by BAL: a 12-year experience in 1066 immunocompromised patients. Respir Med 2006 0.87
111 Improved sensitivity of an interferon-gamma release assay (T-SPOT.TB™) in combination with tuberculin skin test for the diagnosis of latent tuberculosis in the presence of HIV co-infection. BMC Infect Dis 2011 0.87
112 Determinants of sustained viral suppression in HIV-infected patients with self-reported poor adherence to antiretroviral therapy. PLoS One 2012 0.87
113 A comparison of initial antiretroviral therapy in the Swiss HIV Cohort Study and the recommendations of the International AIDS Society-USA. PLoS One 2011 0.86
114 Combined tipranavir and enfuvirtide use associated with higher plasma tipranavir concentrations but not with increased hepatotoxicity: sub-analysis from RESIST. AIDS 2007 0.86
115 Higher risk of incident hepatitis C virus coinfection among men who have sex with men, in whom the HIV genetic bottleneck at transmission was wide. J Infect Dis 2014 0.85
116 Cost-effectiveness of genotypic antiretroviral resistance testing in HIV-infected patients with treatment failure. PLoS One 2007 0.84
117 Co-trimoxazole prophylaxis is associated with reduced risk of incident tuberculosis in participants in the Swiss HIV Cohort Study. Antimicrob Agents Chemother 2014 0.83
118 Low postseroconversion CD4 count and rapid decrease of CD4 density identify HIV+ fast progressors. AIDS Res Hum Retroviruses 2010 0.83
119 Lung resection in hematologic patients with pulmonary invasive fungal disease. Chest 2012 0.83
120 Genetic diversity of EBV-encoded LMP1 in the Swiss HIV Cohort Study and implication for NF-Κb activation. PLoS One 2012 0.83
121 Low-Dose Acetylsalicylic Acid Treatment and Impact on Short-Term Mortality in Staphylococcus aureus Bloodstream Infection: A Propensity Score-Matched Cohort Study. Crit Care Med 2016 0.82
122 Moving up from 3 by 5. Lancet Infect Dis 2006 0.82
123 Body fat changes among antiretroviral-naive patients on PI- and NNRTI-based HAART in the Swiss HIV cohort study. Antivir Ther 2005 0.81
124 Development of HIV drug resistance and therapeutic failure in children and adolescents in rural Tanzania: an emerging public health concern. AIDS 2017 0.81
125 Dose-dependent influence of didanosine on immune recovery in HIV-infected patients treated with tenofovir. AIDS 2005 0.81
126 Intravenous opiate maintenance in a cohort of injecting drug addicts. Drug Alcohol Depend 2003 0.81
127 CD4/CD8 ratio and CD8 counts predict CD4 response in HIV-1-infected drug naive and in patients on cART. Medicine (Baltimore) 2016 0.81
128 cART prescription trends in a prospective HIV cohort in rural Tanzania from 2007 to 2011. BMC Infect Dis 2014 0.80
129 A pain in the neck: probiotics for ulcerative colitis. Ann Intern Med 2009 0.80
130 Randomized trial of a computerized coronary heart disease risk assessment tool in HIV-infected patients receiving combination antiretroviral therapy. Antivir Ther 2010 0.80
131 Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study. AIDS 2007 0.80
132 A longitudinal analysis of healthcare costs after treatment optimization following genotypic antiretroviral resistance testing: does resistance testing pay off? Antivir Ther 2006 0.80
133 The decision to get vaccinated against influenza. Am J Med 2004 0.80
134 Safety and efficacy of once-daily nevirapine dosing: a multicohort study. Antivir Ther 2009 0.80
135 Long-term virological response to multiple sequential regimens of highly active antiretroviral therapy for HIV infection. Antivir Ther 2004 0.80
136 Implementation and Operational Research: An Integrated and Comprehensive Service Delivery Model to Improve Pediatric and Maternal HIV Care in Rural Africa. J Acquir Immune Defic Syndr 2016 0.79
137 Influenza vaccine response profiles are affected by vaccine preparation and preexisting immunity, but not HIV infection. Hum Vaccin Immunother 2015 0.79
138 Chest pain after travel to the tropics. Lancet 2004 0.79
139 Risk of cardiovascular events and blood pressure control in hypertensive HIV-infected patients: Swiss HIV Cohort Study (SHCS). J Acquir Immune Defic Syndr 2013 0.79
140 Inflammatory bowel perforation during immune restoration after one year of antiretroviral and antituberculous therapy in an HIV-1-infected patient: report of a case. Dis Colon Rectum 2002 0.79
141 Is switching to an oral antibiotic regimen safe after 2 weeks of intravenous treatment for primary bacterial vertebral osteomyelitis? BMC Infect Dis 2014 0.78
142 Small dense lipoproteins, apolipoprotein B, and risk of coronary events in HIV-infected patients on antiretroviral therapy: the Swiss HIV Cohort Study. J Acquir Immune Defic Syndr 2012 0.78
143 Emergence of glutaraldehyde-resistant Pseudomonas aeruginosa. Infect Control Hosp Epidemiol 2011 0.78
144 Sexual risk behavior in HIV-infected injection drug users. Clin Infect Dis 2004 0.78
145 Low levels of mannan-binding lectin or ficolins are not associated with an increased risk of cytomegalovirus disease in HIV-infected patients. PLoS One 2013 0.78
146 Replicative phenotyping adds value to genotypic resistance testing in heavily pre-treated HIV-infected individuals--the Swiss HIV Cohort Study. J Transl Med 2011 0.78
147 Gynecomastia and potent antiretroviral therapy. AIDS 2004 0.78
148 Antiretroviral monotherapy: should we abandon the principles of successful antiretroviral therapy? AIDS 2010 0.78
149 Drug-drug interaction in a kidney transplant recipient receiving HIV salvage therapy and tacrolimus. Am J Kidney Dis 2009 0.77
150 The individualized genetic barrier predicts treatment response in a large cohort of HIV-1 infected patients. PLoS Comput Biol 2013 0.77
151 Less than 28 days of intravenous antibiotic treatment is sufficient for suppurative thrombophlebitis in injection drug users. Clin Infect Dis 2008 0.77
152 Symptom manageability in Swiss HIV-infected patients. Appl Nurs Res 2013 0.77
153 Mycobacterium intracellulare infection in non-HIV infected patient in a region with a high burden of tuberculosis. BMJ Case Rep 2012 0.77
154 Influence of antiretroviral therapy on programmed death-1 (CD279) expression on T cells in lymph nodes of human immunodeficiency virus-infected individuals. Hum Pathol 2009 0.77
155 When time is more than money: the allocation of time between work and leisure in HIV-infected patients. Soc Sci Med 2007 0.77
156 Correction: A Bundle of Services Increased Ascertainment of Tuberculosis among HIV-Infected Individuals Enrolled in a HIV Cohort in Rural Sub-Saharan Africa. PLoS One 2015 0.77
157 Hierarchical modeling gave plausible estimates of associations between metabolic syndrome and components of antiretroviral therapy. J Clin Epidemiol 2008 0.77
158 Contrary to HIV, hepatitis C virus is not associated with erythrocytes in vivo. J Hepatol 2005 0.77
159 Interactions of the hepatitis C virus protease inhibitor faldaprevir with cytochrome P450 enzymes: in vitro and in vivo correlation. J Clin Pharmacol 2015 0.77
160 Evidence for prevention and screening: recommendations in adults. Swiss Med Wkly 2002 0.76
161 The J-Curve in HIV: Low and Moderate Alcohol Intake Predicts Mortality but Not the Occurrence of Major Cardiovascular Events. J Acquir Immune Defic Syndr 2016 0.76
162 HIV resistance testing and detected drug resistance in Europe. AIDS 2015 0.76
163 Infections requiring hospitalization of injection drug users who participated in an injection opiate maintenance program. Clin Infect Dis 2002 0.76
164 Impact of body weight on virological and immunological responses to efavirenz-containing regimens in HIV-infected, treatment-naive adults. AIDS 2015 0.76
165 A comment on Marschall et Al. Clin Infect Dis 2011 0.75
166 Do we need national guidelines on human immunodeficiency virus treatment? Enferm Infecc Microbiol Clin 2012 0.75
167 Factors associated with syphilis incidence in the HIV-infected in the era of highly active antiretrovirals. Medicine (Baltimore) 2017 0.75
168 Impact of HIV status on outcome of infectious complications in intravenous drug users. J Acquir Immune Defic Syndr 2009 0.75
169 Immune recovery in HIV-infected patients after Candida esophagitis is impaired despite long-term antiretroviral therapy. AIDS 2016 0.75
170 Two versus three-class antiretroviral therapy in antiretroviral-naive patients in different time periods of the HAART era. AIDS 2007 0.75
171 Impact of protease polymorphisms and viral fitness on human immunodeficiency virus (HIV) type 1 viremia in untreated HIV-1 infection. J Infect Dis 2002 0.75
172 Life expectancy in HIV-positive persons in Switzerland: matched comparison with general population. AIDS 2016 0.75
173 The brain entry of HIV-1 protease inhibitors is facilitated when used in combination. Mol Pharm 2013 0.75
174 Skin problems in immunodeficient patients. Curr Probl Dermatol 2012 0.75
175 Round-table multidisciplinary counselling of couples with HIV prior to assisted reproduction. Reprod Biomed Online 2008 0.75
176 Beneficial course of two cases of HIV-associated multicentric Castleman disease treated with HIV antiretroviral therapy. AIDS 2012 0.75
177 [Ready for antiretroviral therapy? Therapy decision making experiences of persons living with HIV]. Pflege 2005 0.75
178 [The skin, an interdisciplinary organ]. Internist (Berl) 2009 0.75
179 Adverse events of raltegravir and dolutegravir: a prospective analysis of 4,041 HIV-infected individuals from the Swiss HIV Cohort Study. AIDS 2017 0.75
180 Protease inhibitor-sparing simplified maintenance therapy: a need for perspective. J Antimicrob Chemother 2004 0.75
181 Increased Epstein-Barr virus-specific antibody-levels in HIV-infected individuals developing primary central nervous system lymphoma. AIDS 2007 0.75
182 Evaluation of unstructured medical school examinations: prospective observational study. Swiss Med Wkly 2003 0.75
183 Ecological study of the predictors of successful management of dyslipidemia in HIV-infected patients on ART: the Swiss HIV Cohort Study. HIV Clin Trials 2007 0.75
184 Potential benefit and limitations of a broad access to potent antiretroviral therapy in developing countries. Expert Opin Investig Drugs 2002 0.75
185 Discontinuation of enfuvirtide in heavily pretreated HIV-infected individuals. HIV Clin Trials 2009 0.75
186 Once-daily directly observed therapy lopinavir/ritonavir plus indinavir as a protease inhibitor-only salvage therapy in heavily pretreated HIV-1-infected patients: a pilot study. AIDS 2006 0.75
187 Anxiety in health care workers after exposure to potentially HIV-contaminated blood or body fluids. Swiss Med Wkly 2002 0.75
188 Dolutegravir plasma levels after gastric bypass surgery. AIDS 2017 0.75
189 Optimising the performance of an outpatient setting. Swiss Med Wkly 2004 0.75
190 [57-year-old patient with unclear cutaneous finding]. Dtsch Med Wochenschr 2016 0.75
191 HIV-positive child with epidermodysplasia verruciformis-like lesions and homozygous mutation in TMC6. AIDS 2010 0.75